BTIS
CRSP icon

BB&T Investment Services’s CRISPR Therapeutics CRSP Stock Holding History

BB&T Investment Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$23K Hold
1,000
– – ﹤0.01% 765
2017
Q3 		$18K Buy
+1,000
New +$18.1K ﹤0.01% 745

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BB&T Investment Services's CRSP Position: Q4 2017 in Review

BB&T Investment Services held its CRISPR Therapeutics (CRSP) position steady in Q4 2017 at 1,000 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

BB&T Investment Services first reported a position in CRSP in Q3 2017 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold CRSP as of Q4 2017.

  • BB&T Investment Services held 1,000 shares of CRISPR Therapeutics worth $23K as of Q4 2017.
  • BB&T Investment Services left its CRISPR Therapeutics share count unchanged in Q4 2017.
  • CRISPR Therapeutics made up ﹤0.01% of BB&T Investment Services's portfolio in Q4 2017, its #765 holding.
  • BB&T Investment Services first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2017.

Based on BB&T Investment Services's 13F filing for Q4 2017, filed 15 Feb 2018.